GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CNS Pharmaceuticals
CNS Pharmaceuticals is a biotech company developing drugs to treat brain cancer. Its stock price is highly volatile, driven by news about the progress of clinical trials in one of the most complex areas of oncology.
Share prices of companies in the market segment - Cancer brain
CNS Pharmaceuticals is an oncology company developing brain cancer drugs that can cross the blood-brain barrier. We've categorized it as "Brain Cancer." The chart below shows how investors value companies working on this challenging medical challenge.
Broad Market Index - GURU.Markets
CNS Pharmaceuticals is a biopharmaceutical company developing drugs to treat brain cancer and other central nervous system tumors. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CNSP - Daily change in the company's share price CNS Pharmaceuticals
CNS Pharmaceuticals, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its brain cancer drugs.
Daily change in the price of a set of shares in a market segment - Cancer brain
CNS Pharmaceuticals specializes in developing drugs to treat brain cancer, one of the most complex and risky areas in oncology. The chart below illustrates the high volatility typical of this segment, reflecting the enormous risks and potential breakthroughs companies like CNSP face.
Daily change in the price of a broad market stock, index - GURU.Markets
CNS Pharmaceuticals is a biotech company developing drugs to treat brain cancer. Its shares are a bet on a breakthrough in one of the most complex areas of oncology. Their high volatility reflects the significant risks and expectations affecting the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CNS Pharmaceuticals
CNS Pharmaceuticals' year-to-date performance is a story about the development of its brain cancer drug. Its 12-month market cap depends entirely on clinical trial data. The success of its lead candidate, berubicin, which can cross the blood-brain barrier, could be a breakthrough in the treatment of glioblastoma.
Annual dynamics of market capitalization of the market segment - Cancer brain
As an early-stage biotech company, CNS is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its brain cancer drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CNS Pharmaceuticals, an oncology company developing drugs to treat brain cancer, particularly glioblastoma, is working on one of the deadliest forms of cancer. Its year-over-year market capitalization is a story of hope for a breakthrough. The success of its lead candidate could significantly extend patients' lives.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CNS Pharmaceuticals
CNS Pharmaceuticals is an oncology company developing drugs for the treatment of brain tumors. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its lead drug is a key event, triggering strong investor reactions.
Monthly dynamics of market capitalization of the market segment - Cancer brain
Developing drugs for brain cancer is one of the most challenging areas in oncology. The dynamics of this biotech sector, shown in the graph, reflect the extremely high risks and equally high need for new treatments. CNS Pharmaceuticals is one company working in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CNS Pharmaceuticals is a clinical-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on trial data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CNS Pharmaceuticals
CNS Pharmaceuticals, a company developing drugs to treat brain cancer, operates in one of the most complex areas of oncology. Its weekly stock price is a direct response to clinical trial data, where the slightest positive news can spark massive investor interest.
Weekly dynamics of market capitalization of the market segment - Cancer brain
CNS Pharmaceuticals is an oncology company developing a drug to treat glioblastoma, an aggressive form of brain cancer. Its future depends entirely on the success of clinical trials. The chart clearly demonstrates how its shares exist in a world of their own, independent of market trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CNS Pharmaceuticals is an oncology company whose future depends entirely on the success of its clinical trials. The chart clearly demonstrates how its shares exist in a world of their own, independent of general market trends and macroeconomic data.
Market capitalization of the company, segment and market as a whole
CNSP - Market capitalization of the company CNS Pharmaceuticals
CNS Pharmaceuticals' market capitalization chart reflects investors' bets on its flagship brain cancer drug. Its performance reflects the market's belief that its blood-brain barrier-crossing drug will help patients with glioblastoma. Its low valuation is a bet on success in one of the most challenging areas of oncology.
CNSP - Share of the company's market capitalization CNS Pharmaceuticals within the market segment - Cancer brain
CNS Pharmaceuticals develops drugs to treat brain cancer and other CNS tumors. Its market share in the oncology sector is negligible, but it is targeting one of the most challenging areas. Its capitalization is based on its lead drug, berubicin, which is able to cross the blood-brain barrier.
Market capitalization of the market segment - Cancer brain
This chart shows the overall market capitalization of the entire oncology sector. For CNS Pharmaceuticals, which focuses on treating brain cancer, this line maps the battle against the most complex form of cancer. The rising chart shows how investors are willing to fund even the riskiest research in hopes of a breakthrough.
Market capitalization of all companies included in a broad market index - GURU.Markets
CNS Pharmaceuticals develops drugs to treat brain cancer. Its market cap is yet another bet on a breakthrough in one of the most challenging areas of oncology. In the overall market, this represents a tiny fraction of hope for patients with central nervous system tumors.
Book value capitalization of the company, segment and market as a whole
CNSP - Book value capitalization of the company CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs to treat brain cancer. Its book value represents its financial resources for research. It consists of cash that allows the company to conduct clinical trials of its lead candidate. How has this capital changed? The chart below shows.
CNSP - Share of the company's book capitalization CNS Pharmaceuticals within the market segment - Cancer brain
CNS Pharmaceuticals is an oncology company developing drugs for the treatment of brain cancer. Its flagship drug, Berubicin, requires manufacturing infrastructure to produce it for clinical trials. The chart shows its share of the tangible assets required for this complex pharmaceutical development.
Market segment balance sheet capitalization - Cancer brain
CNS Pharmaceuticals is an oncology company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. CNS focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
CNS Pharmaceuticals' assets are not factories, but capital allocated to clinical trials of its lead drug candidate, which can cross the blood-brain barrier for the treatment of brain cancer. These assets reflect its financial resources for fighting this complex disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CNS Pharmaceuticals
CNS Pharmaceuticals is an oncology company developing drugs for brain cancer. Its market capitalization is a bet on its ability to cross the blood-brain barrier and deliver drugs to one of the most difficult-to-treat tumors.
Market to book capitalization ratio in a market segment - Cancer brain
CNS Pharmaceuticals develops drugs to treat brain cancer, one of the most complex areas in oncology. Its high valuation on this chart reflects investors' pure faith in its scientific approach, despite the extremely high risk of clinical failure.
Market to book capitalization ratio for the market as a whole
CNS Pharmaceuticals is targeting brain cancer, one of the most challenging areas in oncology. The company's market value reflects its hopes for a breakthrough in this field. This chart shows the risk investors are willing to take when investing in companies solving complex medical problems.
Debts of the company, segment and market as a whole
CNSP - Company debts CNS Pharmaceuticals
CNS Pharmaceuticals, a company developing drugs to treat brain cancer, is entirely dependent on external funding. This chart illustrates the enormous financial costs and extremely high risks associated with attempting to develop a cure for one of the deadliest cancers.
Market segment debts - Cancer brain
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs to treat brain cancer, particularly glioblastoma, one of the most deadly types of cancer. This chart shows how the company funds its high-risk clinical trials, aiming to offer hope to patients with very limited treatment options.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. Penetrating the blood-brain barrier is one of the most challenging tasks in pharmacology. This chart shows how the company uses debt to fund its high-risk, but potentially breakthrough, oncology research.
Market segment debt to market segment book capitalization - Cancer brain
CNS Pharmaceuticals is an oncology company developing drugs to treat brain cancer, one of the most complex problems in medicine due to the blood-brain barrier. This chart shows how the company finances its risky clinical trials, relating its debt structure to the overall biotech landscape.
Debt to book value of all companies in the market
CNS Pharmaceuticals specializes in developing drugs to treat brain cancer. This is one of the most complex areas in oncology, with a high failure rate in clinical trials. How dependent is the company on debt? This chart of total market debt helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - CNS Pharmaceuticals
CNS Pharmaceuticals is a preclinical biopharmaceutical company developing drugs for the treatment of brain cancer. This chart shows how investors value its lead candidate. The valuation is highly speculative and depends on future clinical trial results.
P/E of the market segment - Cancer brain
CNS Pharmaceuticals is a biopharmaceutical company developing drugs to treat brain cancer and other central nervous system tumors. This chart illustrates the average valuation in the oncology development sector, where developing drugs for brain cancer is one of the most complex, yet important, challenges.
P/E of the market as a whole
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for brain cancer and other central nervous system tumors. This chart reflects investors' overall risk appetite. It helps understand whether CNSP's valuation is based on the potential of its lead drug or whether it moves in line with overall sentiment in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs to treat brain cancer, specifically glioblastoma. Its lead candidate is designed to overcome tumor resistance to chemotherapy. This chart reflects investor hopes for a breakthrough in the treatment of one of the deadliest cancers and the commercial potential of the company's drug.
%20P%2FE%20CNS%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CNS-Pharmaceuticals&v=1772513859292 "Chart of the company's future (projected) P/E CNS Pharmaceuticals")
Future (projected) P/E of the market segment - Cancer brain
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. This is one of the most complex areas of oncology. The chart compares CNS's future profitability expectations with the sector, helping to assess how high investor expectations are for its drug candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-brain&v=1772513859317 "Future (projected) P/E graph of the market segment - Cancer brain")
Future (projected) P/E of the market as a whole
CNS Pharmaceuticals is developing drugs for the treatment of brain cancer that can cross the blood-brain barrier. This is a key scientific challenge in neuro-oncology. This risk appetite chart is an indicator of investor willingness to fund companies solving fundamental problems in medicine with a high risk of failure.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513859380 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CNS Pharmaceuticals
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat brain cancer. Its lead candidate is capable of crossing the blood-brain barrier, a major therapeutic challenge. This chart shows investments in solving one of the most complex problems in oncology.
Profit of companies in the market segment - Cancer brain
CNS Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of brain cancer, including glioblastoma, one of the most aggressive tumors. This chart shows the overall profitability of the brain cancer treatment sector, where there is a pressing need for new therapies that can cross the blood-brain barrier.
Overall market profit
CNS Pharmaceuticals is developing drugs to treat brain cancer. The company is in clinical trials. Its future depends entirely on the success of these studies. The overall economic environment, as shown in this chart, does not impact the need for innovative treatments for these aggressive forms of cancer.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. Future profits depend entirely on the success of its lead candidate, which can cross the blood-brain barrier. This chart reflects analysts' hopes for a breakthrough in the treatment of one of the deadliest forms of cancer.
%20profit%20of%20the%20company%20CNS%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CNS-Pharmaceuticals&v=1772513859576 "Graph of future (projected) profit of the company CNS Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Cancer brain
CNS Pharmaceuticals specializes in developing drugs to treat brain cancer and other central nervous system tumors. Its lead drug is capable of crossing the blood-brain barrier to deliver the drug to the tumor. This chart shows revenue projections for the brain cancer treatment sector, helping to assess the potential of CNS technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-brain&v=1772513859592 "Graph of future (predicted) profits of companies in a market segment - Cancer brain")
Future (predicted) profit of the market as a whole
CNS Pharmaceuticals is a biopharmaceutical company developing drugs to treat brain cancer. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513859629 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CNS Pharmaceuticals
CNS Pharmaceuticals is a clinical-stage oncology company developing drugs to treat brain cancer. It has no revenue. This chart reflects investor hopes for its lead drug, which can cross the blood-brain barrier—the main obstacle in treating brain tumors.
P/S market segment - Cancer brain
CNS Pharmaceuticals is a preclinical biopharmaceutical company developing drugs for the treatment of brain cancer and other central nervous system tumors. Their lead candidate is able to cross the blood-brain barrier, a key therapeutic challenge. This chart reflects the average revenue estimate for the sector, helping to assess the potential of this technology.
P/S of the market as a whole
CNS Pharmaceuticals is developing drugs for the treatment of brain cancer that can cross the blood-brain barrier. This chart highlights that the valuation of such companies is based on their ability to solve one of the most challenging problems in oncology, which could lead to a very high valuation if clinical trials are successful.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs for the treatment of brain cancer, particularly glioblastoma, one of the most aggressive types of cancer. Its lead drug is designed to overcome tumor resistance to chemotherapy. Its revenue estimates are crucial, reflecting investors' expectations that its drug will improve treatment outcomes for these seriously ill patients.
%20P%2FS%20CNS%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CNS-Pharmaceuticals&v=1772513859733 "The graph of the company's future (projected) P/S CNS Pharmaceuticals")
Future (projected) P/S of the market segment - Cancer brain
CNS Pharmaceuticals is a biopharmaceutical company developing drugs to treat brain cancer, including glioblastoma. This chart compares the company's estimated future sales with expectations for the oncology sector. It shows how investors view the potential of its lead drug candidate, which can cross the blood-brain barrier and reach tumors.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20brain&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-brain&v=1772513859752 "Future (projected) P/S market segment graph - Cancer brain")
Future (projected) P/S of the market as a whole
CNS Pharmaceuticals is developing brain cancer treatments that can penetrate the blood-brain barrier, which prevents most drugs from reaching tumors. The company's future depends on the success of this complex undertaking. This market forecast chart reflects investor hopes for a breakthrough in the treatment of one of the most deadly forms of cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513859778 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CNS Pharmaceuticals
This indicator for CNS Pharmaceuticals reflects the financial activity of the company, which is developing drugs for the treatment of brain cancer. Its lead candidate crosses the blood-brain barrier. Being in clinical trials, the company has no commercial revenue.
Sales of companies in the market segment - Cancer brain
CNS Pharmaceuticals is a clinical-stage oncology company developing drugs for the treatment of brain cancer. Its lead candidate, bermekvib, targets glioblastoma, one of the most aggressive forms of cancer. The company's future revenue is entirely dependent on the success of this drug in clinical trials.
Overall market sales
CNS Pharmaceuticals specializes in developing drugs to treat brain cancer and other central nervous system tumors. This is one of the most complex areas in oncology. This overall economic outlook is irrelevant to a company whose mission is to offer hope to patients with difficult-to-treat diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CNS Pharmaceuticals
CNS Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of brain and central nervous system cancers. Its lead drug candidate, berubicin, is intended for the treatment of glioblastoma. Future revenue is dependent on the success of clinical trials. The chart reflects analyst expectations for the potential of this drug.
%20sales%20of%20the%20company%20CNS%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CNS-Pharmaceuticals&v=1772513859860 "Schedule of future (projected) sales of the company CNS Pharmaceuticals")
Future (projected) sales of companies in the market segment - Cancer brain
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. This chart shows revenue forecasts for the entire oncology market. How do scientific breakthroughs in crossing the blood-brain barrier influence analyst expectations? This sets the stage for the company.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-brain&v=1772513859893 "Schedule of future (projected) sales of companies in the market segment - Cancer brain")
Future (projected) sales of the market as a whole
CNS Pharmaceuticals is an oncology company developing drugs to treat brain cancer. Its prospects depend entirely on the success of clinical trials and regulatory approval. The need for effective treatments for aggressive brain tumors is independent of economic conditions, so this schedule is not significant for the company's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513859912 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CNS Pharmaceuticals
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. This chart reflects its financial performance at the clinical trial stage. Profitability depends on the success of its lead candidate, which must overcome the blood-brain barrier—the main obstacle in treating brain tumors.
Market segment marginality - Cancer brain
CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of brain cancer. This chart reflects its financial position, where profitability depends on success in treating one of the most challenging types of cancer, which requires significant investment in R&D.
Market marginality as a whole
CNS Pharmaceuticals specializes in developing drugs for the treatment of brain cancer. The company operates in one of the most complex areas of oncology. Its future depends on the results of clinical trials. This total return chart reflects investors' willingness to fund high-risk but potentially breakthrough medical projects.
Employees in the company, segment and market as a whole
Number of employees in the company CNS Pharmaceuticals
CNS Pharmaceuticals is a clinical-stage biotech company focused on treating brain cancer. Its lead drug was developed at a major oncology clinic. Its small team is working to advance it through clinical trials. This chart shows the compact structure typical of such highly specialized companies.
Share of the company's employees CNS Pharmaceuticals within the market segment - Cancer brain
CNS Pharmaceuticals is an oncology company developing drugs for brain cancer that can cross the blood-brain barrier. This is one of the most challenging areas in pharmaceuticals. This graph shows the company's market share, reflecting its scientific focus and the scale of its R&D program in this narrow but critically important area.
Number of employees in the market segment - Cancer brain
CNS Pharmaceuticals develops drugs to treat brain cancer and other central nervous system tumors. The company's key drug is capable of crossing the blood-brain barrier. The chart shows the workload in the brain oncology sector. This is a key challenge in treating these diseases, and CNS's technology could be a breakthrough.
Number of employees in the market as a whole
CNS Pharmaceuticals is a biopharmaceutical company focused on treating brain cancer, one of the most complex areas in oncology. The company's growth depends entirely on success in clinical trials. In this chart, CNS Pharma represents the world of science, where employment is an investment in the fight against the most serious diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CNS Pharmaceuticals (CNSP)
CNS Pharmaceuticals is a biotech company focused on treating brain cancer, specifically glioblastoma (the drug Berubicin). This is a high-risk, high-reward R&D company. This chart shows how the market values their leading asset. It reflects the market value per employee, which is a bet on the success of their key drug.
%20of%20the%20company%20CNS%20Pharmaceuticals%20(CNSP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CNS-Pharmaceuticals-CNSP&v=1772513860113 "Chart of market capitalization per employee (in thousands of dollars) of the company CNS Pharmaceuticals (CNSP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer brain
CNS Pharmaceuticals (CNSP) is an oncology company developing drugs for the treatment of brain cancer. The company's market capitalization per employee (MCPE) reflects its estimated breakthrough potential. This high value may be due to the fact that its key drug, Berubicin, is able to cross the blood-brain barrier, a key challenge in treating brain tumors.
%20by%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-brain&v=1772513860129 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer brain")
Market capitalization per employee (in thousands of dollars) for the overall market
CNS Pharmaceuticals is an oncology company developing a drug to treat brain cancer. Its valuation is a bet on success in a very complex therapeutic area. The chart shows a high cost per employee, as glioblastoma is a virtually untreatable disease, and any progress in this area will be highly valued by the market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513860147 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CNS Pharmaceuticals (CNSP)
CNS Pharmaceuticals is a clinical-stage biotech company focused on treating brain cancer (glioblastoma). This is one of the most challenging R&D challenges. This chart shows the net loss per employee. It reflects how much capital the company invests in each researcher to conduct expensive clinical trials.
%20Chart%20CNS%20Pharmaceuticals%20(CNSP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CNS-Pharmaceuticals-CNSP&v=1772513860182 "Company Profit Per Employee (in thousands of dollars) Chart CNS Pharmaceuticals (CNSP)")
Profit per employee (in thousands of dollars) in the market segment - Cancer brain
CNS Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs to treat brain cancer. In this highly complex area of oncology, efficiency per employee is critical. This chart shows the financial return on a small but focused team, which is an indicator of progress in the fight against difficult-to-treat diseases.
%20in%20the%20market%20segment%20-%20Cancer%20brain&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-brain&v=1772513860209 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer brain")
Profit per employee (in thousands of dollars) for the market as a whole
CNS Pharmaceuticals is a biotech company focused on treating brain cancer, including glioblastoma. It's an R&D company working in one of the most complex areas of oncology. This graph, showing average profitability, only highlights how biotech, where all the value is in IP, differs from operating businesses.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513860232 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CNS Pharmaceuticals (CNSP)
CNS Pharmaceuticals is an oncology company developing drugs to treat brain cancer. At the clinical stage, this figure is negligible. It reflects the enormous stakes: a successful drug for such a complex target could become a blockbuster and lead to explosive revenue growth per research team member.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CNS-Pharmaceuticals-CNSP&v=1772513860263 "Sales chart per company employee CNS Pharmaceuticals (CNSP)")
Sales per employee in the market segment - Cancer brain
CNS Pharmaceuticals (CNSP) is a clinical-stage biotech focused on treating brain cancer (glioblastoma). Their lead candidate (Berubicin) is designed to cross the blood-brain barrier. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of CNSP's R&D staffing efficiency.
Sales per employee for the market as a whole
CNS Pharmaceuticals (CNSP) is a biotech company focused on developing drugs for the treatment of brain cancer. Their lead candidate is a drug capable of crossing the blood-brain barrier. This chart reflects their R&D status: the company invests in clinical trials and has no commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company CNS Pharmaceuticals (CNSP)
CNS Pharmaceuticals (CNSP) is developing a drug for the treatment of glioblastoma (an aggressive brain cancer) that should better penetrate the blood-brain barrier. This chart shows the volume of bearish bets. "Shorts" reflect the extremely low chances of success in treating this type of cancer.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CNS-Pharmaceuticals-CNSP&v=1772513860307 "Short Shares Chart for the Company CNS Pharmaceuticals (CNSP)")
Shares shorted by market segment - Cancer brain
CNS Pharmaceuticals (CNSP) is an oncology company specializing in developing drugs for the treatment of brain cancer, particularly glioblastoma. Its key drug, Berubicin, is designed to cross the blood-brain barrier. This chart aggregates short positions in the oncology sector, reflecting investor skepticism in this highly complex field.
Shares shorted by the overall market
CNS Pharmaceuticals is a biotech focused on brain cancer, one of the most challenging areas of R&D. This chart reflects the overall market pessimism. When investors are fearful, they're unwilling to bet on R&D with the highest risk of failure. They see a "cash burn" and flee such stocks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CNS Pharmaceuticals (CNSP)
CNS Pharmaceuticals is targeting one of the most challenging targets: treating brain cancer (glioblastoma). It's a biotech with a binary outcome. This graph is a "cardiogram" of hope. It overheats to the extreme on any positive data showing that their drug penetrates the blood-brain barrier.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CNS-Pharmaceuticals-CNSP&v=1772513860331 "RSI 14 indicator chart for the company's stock CNS Pharmaceuticals (CNSP)")
RSI 14 Market Segment - Cancer brain
CNS Pharmaceuticals (CNSP) is a biotech company targeting one of the most challenging cancers: brain cancer (glioblastoma). Their drug, Berubicin, is designed to overcome the blood-brain barrier. This chart measures the pulse of the Oncology/Brain Cancer sector. It helps distinguish CNSP's performance from general overheating or overselling in the biotech sector.
RSI 14 for the overall market
For CNS Pharma (CNSP), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash spigot is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CNSP (CNS Pharmaceuticals)
CNS Pharmaceuticals is a biotech company focused on treating brain cancer, primarily glioblastoma (the most aggressive form). This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their assessment of the success of the clinical trials of Berubicin.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CNSP-CNS-Pharmaceuticals&v=1772513860409 "A chart showing analyst consensus forecasts for the expected stock price. CNSP (CNS Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CNSP (CNS Pharmaceuticals)
CNS Pharmaceuticals is a biotech company whose sole goal is to cross the blood-brain barrier (BBB). Their drug (Berubicin) targets brain cancer. This chart shows the upside and downside potential analysts see in the stock. The gap reflects their confidence in the success of this complex R&D challenge.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CNSP-CNS-Pharmaceuticals&v=1772513860431 "A chart showing the difference between the consensus forecast and the actual stock price. CNSP (CNS Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Cancer brain
CNS Pharmaceuticals is a "last resort" R&D biotech company developing drugs (Berenbostat) for the treatment of the most aggressive brain tumors (glioblastoma). This chart reflects analysts' overall expectations for the entire brain cancer sector. It shows whether experts believe a breakthrough can be achieved in this complex field.
Analysts' consensus forecast for the overall market share price
CNS Pharmaceuticals is a biotech company focused on one of the most complex challenges: treating brain cancer. This is a highly risky area. This chart reflects the overall risk appetite in the market. For CNSP, whose price is a breakout option, overall market optimism (a rising chart) is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CNS Pharmaceuticals
CNS Pharma is a Trojan horse for brain cancer. Their signature drug (Berubicin) is capable (unlike others) of penetrating the blood-brain barrier (BBB) to attack glioblastoma. This graph is a pure indicator of their R&D. Its dynamics are all or nothing, depending entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Cancer brain
CNS Pharmaceuticals targets the most difficult-to-treat cancers—brain tumors. Their drugs must cross the blood-brain barrier, a formidable scientific challenge. This chart compares their composite index to their sector, showing how this risky but important mission impacts their relative position among biotech companies.
The AKIM Index for the overall market
CNS Pharmaceuticals is a biotech company developing new treatments for brain cancer (glioblastoma). Its key asset is Berubicin. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific venture, targeting a complex disease, compares to overall economic trends.
